Amgen Ventures contributed to a series B round for Fortuna Fix, which will use the funding for clinical trials and to expand manufacturing.
Canada-based regenerative medical technology developer Fortuna Fix has secured $25m in series B funding from investors including pharmaceutical firm Amgen’s corporate venturing arm, Amgen Ventures.
The round also featured Macnguyen Family Office as well as Salamander Invest, a special purpose vehicle established by Norwegian institutional investors and family offices to back Fortuna, and undisclosed other investors.
Founded in 2015, Fortuna is developing technology that can reprogram a patient’s own neural stem cells to replace lost neuronal tissue as a treatment…
